Goldman Sachs Upgrades Thoratec (THOR) to Buy; Underestimated
Tweet Send to a FriendGet Alerts THOR Hot Sheet
Price: $31.39 -0.41%
Rating Summary:
12 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
12 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade THOR Now!
Goldman Sachs upgraded Thoratec (NASDAQ: THOR) from Neutral to Buy, raises price target of $45.00.
Analyst, David H. Roman, said, "We believe Street estimates are too bearish on the potential for market expansion to more effectively defend Thoratec’s US share position. We now model 2012-2015E sales growth of 13.3% vs. consensus at 9.9% (tethered to higher aggregate market growth and share assumptions). Higher sales forecasts drive upward revisions to EPS, placing our estimates 13%, 12%, and 8% above the Street in 2013-2015E, respectively. With sustained top-line growth in the low-teens (toward the high end of our MedTech coverage), we see THOR as an attractive fundamental and strategic asset."
For an analyst ratings summary and ratings history on Thoratec click here. For more ratings news on Thoratec click here.
Shares of Thoratec closed at $33.17 yesterday, with a 52 week range of $27.84-$38.07.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, David H. Roman, said, "We believe Street estimates are too bearish on the potential for market expansion to more effectively defend Thoratec’s US share position. We now model 2012-2015E sales growth of 13.3% vs. consensus at 9.9% (tethered to higher aggregate market growth and share assumptions). Higher sales forecasts drive upward revisions to EPS, placing our estimates 13%, 12%, and 8% above the Street in 2013-2015E, respectively. With sustained top-line growth in the low-teens (toward the high end of our MedTech coverage), we see THOR as an attractive fundamental and strategic asset."
For an analyst ratings summary and ratings history on Thoratec click here. For more ratings news on Thoratec click here.
Shares of Thoratec closed at $33.17 yesterday, with a 52 week range of $27.84-$38.07.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, UpgradesRelated Entities
Goldman Sachs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
